MacroGenics | MGNX - Операционные расходы





Операционные расходы Изменить Дата
AbbVie USD 10.52B 258M 2026-09
Amgen USD 5.69B 6B 2026-09
AstraZeneca USD 11.55B 674M 2026-09
Biogen USD 2.32B 663.6M 2026-09
Bristol-Myers Squibb USD 23.4B 1.08B 2026-09
Daiichi Sankyo JPY 483.8B 5.85B 2026-09
Eli Lilly USD 10.52B 496M 2026-06
Genmab DKK 748M 77M 2026-06
Geron USD 54.46M 15.67M 2026-09
Gilead Sciences USD 13.04B 9.09B 2026-09
J&J USD 18.93B 1.09B 2026-09
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
MacroGenics USD 42.87M 21.68M 2026-06
Merck USD 10.75B 5.02B 2026-09
Pfizer USD 89B 3.81B 2026-09
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 33.5B 1.79B 2026-09
Roche Holding CHF 18.9B 2.12B 2026-06
Xencor USD 87.82M 5.44M 2026-06